These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34806783)

  • 1. Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment.
    Láinez MJA; Schoenen J; Stroud C; Bardos J; Bangs M; Kemmer P; Wenzel R; Kuruppu DK; Martinez JM; Oakes TM
    Headache; 2022 Jan; 62(1):65-77. PubMed ID: 34806783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
    Camporeale A; Kudrow D; Sides R; Wang S; Van Dycke A; Selzler KJ; Stauffer VL
    BMC Neurol; 2018 Nov; 18(1):188. PubMed ID: 30413151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
    Bangs ME; Kudrow D; Wang S; Oakes TM; Terwindt GM; Magis D; Yunes-Medina L; Stauffer VL
    BMC Neurol; 2020 Jan; 20(1):25. PubMed ID: 31952501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.
    Dodick DW; Goadsby PJ; Lucas C; Jensen R; Bardos JN; Martinez JM; Zhou C; Aurora SK; Yang JY; Conley RR; Oakes T
    Cephalalgia; 2020 Aug; 40(9):935-948. PubMed ID: 32050782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache.
    Riesenberg R; Gaul C; Stroud CE; Dong Y; Bangs ME; Wenzel R; Martinez JM; Oakes TM
    Cephalalgia; 2022 Oct; 42(11-12):1225-1235. PubMed ID: 35633025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
    Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
    J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine.
    Stauffer VL; Wang S; Bonner J; Kim B; Bhandari R; Day KA; Camporeale A
    BMC Neurol; 2020 May; 20(1):194. PubMed ID: 32429851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies.
    Oakes TM; Kovacs R; Rosen N; Doty E; Kemmer P; Aurora SK; Camporeale A
    Headache; 2020 Jan; 60(1):110-123. PubMed ID: 31721185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A long-term open-label safety study of galcanezumab in Japanese patients with migraine.
    Hirata K; Takeshima T; Sakai F; Tatsuoka Y; Suzuki N; Igarashi H; Nakamura T; Ozeki A; Yamazaki H; Skljarevski V
    Expert Opin Drug Saf; 2021 Jun; 20(6):721-733. PubMed ID: 33393835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache.
    Kudrow D; Andrews JS; Rettiganti M; Oakes T; Bardos J; Gaul C; Riesenberg R; Wenzel R; Kuruppu D; Martinez J
    Headache; 2020 Nov; 60(10):2254-2264. PubMed ID: 33179263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.
    Pozo-Rosich P; Detke HC; Wang S; Doležil D; Li LQ; Aurora SK; Reuter U
    Curr Med Res Opin; 2022 May; 38(5):731-742. PubMed ID: 35392739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Galcanezumab for episodic and chronic cluster headache].
    Pohl H; Holle-Lee D; Broicher SD; Schwerdtner I; Gantenbein AR; Gaul C
    Schmerz; 2023 Jun; 37(3):168-174. PubMed ID: 35476143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.
    Oakes TMM; Skljarevski V; Zhang Q; Kielbasa W; Hodsdon ME; Detke HC; Camporeale A; Saper JR
    Cephalalgia; 2018 May; 38(6):1015-1025. PubMed ID: 29310444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial of Galcanezumab in Prevention of Episodic Cluster Headache.
    Goadsby PJ; Dodick DW; Leone M; Bardos JN; Oakes TM; Millen BA; Zhou C; Dowsett SA; Aurora SK; Ahn AH; Yang JY; Conley RR; Martinez JM
    N Engl J Med; 2019 Jul; 381(2):132-141. PubMed ID: 31291515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug profile: galcanezumab for prevention of cluster headache.
    Mudugal D; Monteith TS
    Expert Rev Neurother; 2021 Feb; 21(2):145-155. PubMed ID: 33206562
    [No Abstract]   [Full Text] [Related]  

  • 18. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
    Detke HC; Goadsby PJ; Wang S; Friedman DI; Selzler KJ; Aurora SK
    Neurology; 2018 Dec; 91(24):e2211-e2221. PubMed ID: 30446596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials.
    Yang Y; Wang Z; Gao B; Xuan H; Zhu Y; Chen Z; Wang Z
    J Headache Pain; 2020 Feb; 21(1):14. PubMed ID: 32046655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.